MA39711A - Conjugués d'une fraction d'il-15 et d'un polymère - Google Patents
Conjugués d'une fraction d'il-15 et d'un polymèreInfo
- Publication number
- MA39711A MA39711A MA039711A MA39711A MA39711A MA 39711 A MA39711 A MA 39711A MA 039711 A MA039711 A MA 039711A MA 39711 A MA39711 A MA 39711A MA 39711 A MA39711 A MA 39711A
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- moiety
- polymer
- nonpeptidic
- methods
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- -1 poly(ethylene glycol) Polymers 0.000 abstract 2
- 229920003169 water-soluble polymer Polymers 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461974914P | 2014-04-03 | 2014-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39711A true MA39711A (fr) | 2015-10-08 |
Family
ID=54241432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA039711A MA39711A (fr) | 2014-04-03 | 2015-03-31 | Conjugués d'une fraction d'il-15 et d'un polymère |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170035898A1 (enExample) |
| EP (2) | EP3919071A1 (enExample) |
| JP (2) | JP6728055B2 (enExample) |
| KR (1) | KR102432169B1 (enExample) |
| CN (1) | CN106456716A (enExample) |
| AU (3) | AU2015240806B2 (enExample) |
| CA (1) | CA2942571C (enExample) |
| ES (1) | ES2876433T3 (enExample) |
| IL (1) | IL248169A0 (enExample) |
| MA (1) | MA39711A (enExample) |
| MX (2) | MX388865B (enExample) |
| WO (1) | WO2015153753A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1215681A1 (zh) | 2013-04-18 | 2016-09-09 | Armo Biosciences, Inc. | 使用白细胞介素-10治疗疾病和病症的方法 |
| ES2688206T3 (es) | 2013-06-17 | 2018-10-31 | Armo Biosciences, Inc. | Procedimiento de evaluación de la identidad y la estabilidad de proteínas |
| CN105658232A (zh) | 2013-08-30 | 2016-06-08 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
| ES2862139T3 (es) | 2013-11-11 | 2021-10-07 | Armo Biosciences Inc | Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos |
| US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
| KR20170068553A (ko) | 2014-10-14 | 2017-06-19 | 아르모 바이오사이언시스 인코포레이티드 | 인터류킨-15 조성물 및 이의 용도 |
| MX2017004983A (es) | 2014-10-22 | 2017-11-13 | Armo Biosciences Inc | Metodos para usar interleucina 10 para tratar enfermedades y trastornos. |
| US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
| HK1248137A1 (zh) | 2015-05-28 | 2018-10-12 | 阿尔莫生物科技股份有限公司 | 用於治疗癌症的聚乙二醇化白细胞介素-10 |
| MX2018002298A (es) | 2015-08-25 | 2018-07-06 | Armo Biosciences Inc | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. |
| WO2017062832A1 (en) | 2015-10-08 | 2017-04-13 | Nektar Therapeutics | Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist |
| MX2018007304A (es) * | 2015-12-21 | 2019-03-14 | Armo Biosciences Inc | Composiciones de interleucina-15 y sus usos. |
| CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| KR102798243B1 (ko) * | 2017-05-15 | 2025-04-18 | 넥타르 테라퓨틱스 | 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법 |
| EP3678701A4 (en) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME |
| TWI834636B (zh) | 2018-02-26 | 2024-03-11 | 美商欣爍克斯公司 | Il-15結合物及其用途 |
| WO2020097556A1 (en) * | 2018-11-09 | 2020-05-14 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent |
| CA3136726A1 (en) * | 2019-04-26 | 2020-10-29 | Prolynx Llc | Slow-release cytokine conjugates |
| US11248025B2 (en) | 2019-06-03 | 2022-02-15 | Medikine, Inc. | IL-2alpha receptor subunit binding compounds |
| MX2022002053A (es) * | 2019-08-23 | 2022-03-17 | Synthorx Inc | Conjugados de il-15 y sus usos. |
| WO2022212362A1 (en) * | 2021-03-29 | 2022-10-06 | Beijing Xuanyi Pharmasciences Co., Ltd. | Protein-macromolecule conjugates and methods of use thereof |
| JP2024526080A (ja) | 2021-06-23 | 2024-07-17 | サイチューン ファーマ | インターロイキン１５多様体 |
| WO2023288226A2 (en) * | 2021-07-12 | 2023-01-19 | Nektar Therapeutics | Polymer engineered forms of interferon-gamma and methods of use |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2025101551A1 (en) * | 2023-11-06 | 2025-05-15 | Regents Of The University Of Minnesota | Prostate-specific membrane antigen (psma)-binding peptides and method of use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| ATE293168T1 (de) * | 1993-11-12 | 2005-04-15 | Gilead Sciences Inc | Thrombin mutanten |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| PT772624E (pt) | 1994-04-06 | 2001-03-30 | Immunex Corp | Interleucina-15 |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US7008624B1 (en) * | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| ES2222689T3 (es) | 1998-03-12 | 2005-02-01 | Nektar Therapeutics Al, Corporation | Derivados del polietilenglicol con grupos reactivos proximales. |
| AU2001238595A1 (en) | 2000-02-22 | 2001-09-03 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| ATE444984T1 (de) * | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| MXPA05007348A (es) | 2003-01-06 | 2005-10-05 | Nektar Therapeutics Al Corp | Derivados de polimeros solubles en agua tiol-selectivos. |
| CA2538083A1 (en) * | 2003-09-25 | 2005-04-07 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
| WO2006017853A2 (en) * | 2004-08-11 | 2006-02-16 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15-containing compositions and suppression of an immune response |
| JP2008515896A (ja) | 2004-10-05 | 2008-05-15 | オクスナー クリニック ファウンデーション | Ｉｌ−１５によるｂ細胞増殖の増強 |
| US20060257361A1 (en) * | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| CA2611823C (en) | 2005-06-16 | 2013-07-30 | Nektar Therapeutics Al, Corporation | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| CN106046370A (zh) | 2007-02-28 | 2016-10-26 | 塞瑞纳治疗公司 | 聚噁唑啉poz化合物、合成其的方法、以及靶分子‑poz偶联物 |
| DK2431741T3 (da) * | 2008-10-21 | 2013-10-21 | Baxter Int | Fremgangsmåde til bestemmelse af virksomme bestanddele i profarmaka-PEG-proteinkonjugat |
| BR112013001611B1 (pt) * | 2010-07-30 | 2022-05-10 | Takeda Pharmaceutical Company Limited | Método para conjugar um polímero solúvel em água a uma fração de carboidrato oxidado de uma proteína terapêutica, proteína terapêutica modificada, método para formar uma ligação oxima entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo amino-óxi ativo emétodo para formar uma ligação hidrazona entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo hidrazida ativo |
| PT2637694T (pt) * | 2010-11-12 | 2021-05-05 | Nektar Therapeutics | Conjugados de uma fração de il-2 e um polímero |
| CN102145178B (zh) * | 2011-04-15 | 2012-09-26 | 北京凯因科技股份有限公司 | Peg化白介素15 |
| WO2013020079A2 (en) * | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
-
2015
- 2015-03-31 MA MA039711A patent/MA39711A/fr unknown
- 2015-04-01 MX MX2016012908A patent/MX388865B/es unknown
- 2015-04-01 US US15/301,681 patent/US20170035898A1/en not_active Abandoned
- 2015-04-01 EP EP21169371.8A patent/EP3919071A1/en active Pending
- 2015-04-01 CN CN201580017361.XA patent/CN106456716A/zh active Pending
- 2015-04-01 KR KR1020167027127A patent/KR102432169B1/ko active Active
- 2015-04-01 CA CA2942571A patent/CA2942571C/en active Active
- 2015-04-01 EP EP15773976.4A patent/EP3139947B8/en active Active
- 2015-04-01 AU AU2015240806A patent/AU2015240806B2/en active Active
- 2015-04-01 ES ES15773976T patent/ES2876433T3/es active Active
- 2015-04-01 JP JP2016559891A patent/JP6728055B2/ja active Active
- 2015-04-01 WO PCT/US2015/023871 patent/WO2015153753A2/en not_active Ceased
-
2016
- 2016-09-30 MX MX2021015492A patent/MX2021015492A/es unknown
- 2016-10-02 IL IL248169A patent/IL248169A0/en active IP Right Grant
-
2019
- 2019-12-16 AU AU2019283778A patent/AU2019283778A1/en not_active Abandoned
-
2020
- 2020-04-20 JP JP2020074680A patent/JP2020114875A/ja not_active Withdrawn
-
2021
- 2021-10-28 AU AU2021258008A patent/AU2021258008A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016012908A (es) | 2017-01-11 |
| WO2015153753A3 (en) | 2015-11-26 |
| JP2020114875A (ja) | 2020-07-30 |
| JP2017511322A (ja) | 2017-04-20 |
| AU2015240806B2 (en) | 2019-09-19 |
| AU2021258008A1 (en) | 2021-11-25 |
| MX388865B (es) | 2025-03-20 |
| AU2019283778A1 (en) | 2020-01-16 |
| US20170035898A1 (en) | 2017-02-09 |
| JP6728055B2 (ja) | 2020-07-22 |
| AU2015240806A1 (en) | 2016-10-13 |
| EP3139947A4 (en) | 2018-01-17 |
| CA2942571C (en) | 2023-09-19 |
| KR20170005793A (ko) | 2017-01-16 |
| EP3139947B8 (en) | 2021-06-30 |
| MX2021015492A (es) | 2022-02-22 |
| CN106456716A (zh) | 2017-02-22 |
| KR102432169B1 (ko) | 2022-08-11 |
| EP3139947A2 (en) | 2017-03-15 |
| IL248169A0 (en) | 2016-11-30 |
| CA2942571A1 (en) | 2015-10-08 |
| EP3139947B1 (en) | 2021-05-26 |
| WO2015153753A2 (en) | 2015-10-08 |
| EP3919071A1 (en) | 2021-12-08 |
| ES2876433T3 (es) | 2021-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015492A (es) | Conjugados de un resto de interleucina-15 (il-15) y un polimero. | |
| MX2017011562A (es) | Conjugados de un resto de il-7 y un polimero. | |
| MX382791B (es) | Conjugados novedosos de glicano y uso de los mismos | |
| SG10201909805XA (en) | Surface modified polymer compositions | |
| MX2016009943A (es) | Composiciones de nanotribologia y metodos relacionados que incluyen nanolaminas moleculares. | |
| WO2016040369A3 (en) | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS | |
| MX381160B (es) | Agonistas del receptor de apelina y metodos de uso. | |
| MX358399B (es) | Conjugados de un resto de interleucina-2 y un polímero. | |
| CY1124425T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης | |
| PH12017500555A1 (en) | Modified phosphpors and compositions thereof | |
| EP3037475A4 (en) | Phenoxy cyclotriphosphazene active ester, halogen-free resin composition and use thereof | |
| WO2015168225A3 (en) | Alkoxy polycarbonates, bisphenol monomers and methods of making and using the same | |
| PH12013501311A1 (en) | Polymer systems | |
| EP3510117A4 (en) | GLYOXALATED LIGNIN COMPOSITIONS | |
| ZA201803476B (en) | Anti-cd22 antibody-maytansine conjugates and methods of use thereof | |
| WO2013020079A3 (en) | Conjugates of an il-11 moiety and a polymer | |
| MX385886B (es) | Macromoleculas estrellas compatibles con tensoactivos. | |
| MY181478A (en) | Mixed decyl mercaptans compositions and methods of making same | |
| MX2018005085A (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos de fabricacion y uso de las mismas. | |
| MY191782A (en) | A process to prepare a polyester polymer and a polyester polymer obtainable thereby | |
| TW201614007A (en) | Composition for forming silica layer, silica layer, and electronic device | |
| MX2020002908A (es) | Composicion acuosa de polimeros. | |
| PH12018000199B1 (en) | Compositions containing polymeric carbodiimide, epoxide and polyester-based polymers, their production and use | |
| MX2016010229A (es) | Conjugados del factor vii. | |
| EA201890073A1 (ru) | Получение 2,5,6-тригидрокси-3-гексеновой кислоты и 2,5-дигидрокси-3-пентеновой кислоты и их сложных эфиров из с6 и с5 сахаров |